[go: up one dir, main page]

RU2518892C2 - Лиганды для агрегированных молекул тау-белка - Google Patents

Лиганды для агрегированных молекул тау-белка

Info

Publication number
RU2518892C2
RU2518892C2 RU2011107931/04A RU2011107931A RU2518892C2 RU 2518892 C2 RU2518892 C2 RU 2518892C2 RU 2011107931/04 A RU2011107931/04 A RU 2011107931/04A RU 2011107931 A RU2011107931 A RU 2011107931A RU 2518892 C2 RU2518892 C2 RU 2518892C2
Authority
RU
Russia
Prior art keywords
protein
tau
compound
formula
phf
Prior art date
Application number
RU2011107931/04A
Other languages
English (en)
Other versions
RU2011107931A (ru
Inventor
Стивен Джон КЕМП
Линда Джейн СТОРИ
Джон Мервин Дэвид Стори
Дженет РИККАРД
Чарльз Роберт Харрингтон
Клод Мишель Вишик
Скотт Клунас
Тобиас Керст ХЕЙНРИЧ
Original Assignee
Виста Лабораториз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виста Лабораториз Лтд. filed Critical Виста Лабораториз Лтд.
Publication of RU2011107931A publication Critical patent/RU2011107931A/ru
Application granted granted Critical
Publication of RU2518892C2 publication Critical patent/RU2518892C2/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/18—Sulfur containing

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к способу маркировки парных спиральных филаментов (PHF), включающему взаимодействие PHF с соединением и детектирование присутствия указанного соединения, где соединение имеет формулу, в которой -R- означает,-Q- выбран из: -NHC(O)-, -N=N-, -CH=CH-; -P выбран из:;-T выбран из:; X представляет собой N или CH; -W, -G, -Рявляются такими, как указано в формуле изобретения. Также изобретение относится к способу маркировки агрегированного тау-белка, включающему взаимодействие агрегированных молекул тау-белка с соединением и детектирование присутствия указанного соединения, и к самим соединениям формулы, в которой значения заместителей являются такими, как указано в формуле изобретения. Технический результат - соединения формулыв качестве меток тау-белка и парных спиральных филаментов (PHF). 6 н. и 22 з.п. ф-лы, 5 ил., 225 пр.
RU2011107931/04A 2008-09-23 2009-09-23 Лиганды для агрегированных молекул тау-белка RU2518892C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9937608P 2008-09-23 2008-09-23
US61/099,376 2008-09-23
PCT/GB2009/002260 WO2010034982A1 (en) 2008-09-23 2009-09-23 Ligands for aggregated tau molecules

Publications (2)

Publication Number Publication Date
RU2011107931A RU2011107931A (ru) 2012-10-27
RU2518892C2 true RU2518892C2 (ru) 2014-06-10

Family

ID=41478644

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011107931/04A RU2518892C2 (ru) 2008-09-23 2009-09-23 Лиганды для агрегированных молекул тау-белка

Country Status (20)

Country Link
US (1) US8895313B2 (ru)
EP (1) EP2338059B1 (ru)
JP (1) JP5667058B2 (ru)
KR (1) KR101631727B1 (ru)
CN (1) CN102224423B (ru)
AU (1) AU2009295701B2 (ru)
BR (1) BRPI0919079B1 (ru)
CA (1) CA2737028C (ru)
DK (1) DK2338059T3 (ru)
ES (1) ES2540536T3 (ru)
HK (1) HK1159247A1 (ru)
HR (1) HRP20150724T1 (ru)
IL (1) IL211369A (ru)
MX (1) MX2011002647A (ru)
PL (1) PL2338059T3 (ru)
PT (1) PT2338059E (ru)
RU (1) RU2518892C2 (ru)
SI (1) SI2338059T1 (ru)
WO (1) WO2010034982A1 (ru)
ZA (1) ZA201102159B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2721845C2 (ru) * 2015-12-30 2020-05-25 Нойборон Медтех Лтд. СОЕДИНЕНИЕ ДЛЯ СПЕЦИФИЧЕСКОГО СВЯЗЫВАНИЯ С β-АМИЛОИДОМ

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2427463A1 (en) * 2009-05-05 2012-03-14 Limited Liability Company "Innovative Pharma" Imidazo [1, 2 -a] pyridin-2 -yl-phenyl derivatives to be used in cancer treatment
CN102250134B (zh) * 2010-05-21 2013-12-04 中国科学院化学研究所 一种识别氟离子的荧光探针及其制备方法和用途
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
EP2671885A1 (en) * 2012-06-05 2013-12-11 Ares Trading S.A. Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
RU2015106437A (ru) * 2012-08-14 2016-10-10 Ф.Хоффманн-Ля Рош Аг Производные имидазо[2,1]тиазол-3-она, пригодные в качестве диагностических агентов для болезни альцгеймера
US10604516B2 (en) * 2012-12-21 2020-03-31 National Institutes For Quantum And Radiological Science And Technology Compounds for imaging tau proteins that accumulate in the brain
MX2015014353A (es) * 2013-04-29 2016-04-07 Hoffmann La Roche Derivados de 2-fenil- o 2-hetaril-imidazol[1,2-a]piridina.
KR101770532B1 (ko) * 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
JP6754353B2 (ja) 2014-08-29 2020-09-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
CN104557768B (zh) * 2014-12-09 2016-09-14 温州大学 一种苯并噻唑衍生物的合成方法
CN107427517B (zh) 2015-02-24 2021-11-16 国立大学法人鸟取大学 用于痴呆症的预防及/或治疗的医药
WO2016148114A1 (ja) * 2015-03-13 2016-09-22 国立大学法人北海道大学 酸化ストレス誘導神経細胞死抑制化合物
CN107949383B (zh) * 2015-08-18 2022-08-23 加利福尼亚大学董事会 用于成像的含氮氧化合物的淀粉样蛋白结合剂
CN106496275A (zh) * 2016-09-07 2017-03-15 北京师范大学 与Aβ斑块具有高亲和力的N2S2类2‑芳基苯并噻唑化合物及其制备方法与应用
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
JP7293343B2 (ja) * 2018-05-09 2023-06-19 アプリノイア セラピューティクス リミテッド ヘテロアリール化合物及びその使用
CA3124898C (en) * 2018-12-29 2023-08-22 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound, intermediate, preparation method therefor and application thereof
KR102215255B1 (ko) * 2019-06-12 2021-02-15 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 형광 탐침자로서 유효한 신규 화합물 및 이의 제조 방법
KR102132847B1 (ko) * 2019-12-09 2020-07-13 한국과학기술연구원 타우 응집체에 높은 선택성을 가지는 화합물, 이를 포함하는 타우 표적 프로브, 및 이의 제조 방법
GB202213796D0 (en) 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
WO2024145662A1 (en) * 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL265443A (ru) 1960-06-02
CH484918A (de) 1965-10-28 1970-01-31 Ciba Geigy Verfahren zur Herstellung heterocyclischer, Aethylendoppelbindungen enthaltender Verbindungen
CH542266A (de) 1966-09-23 1973-09-30 Ciba Geigy Ag Verwendung von Styryl-Verbindungen als optische Aufhellmittel für organische Materialien ausserhalb der Textilindustrie
US3615639A (en) * 1967-10-23 1971-10-26 Eastman Kodak Co Direct positive silver halide emulsions containing dyes as electron acceptors and spectral sensitizers
JPS51102186A (ru) 1975-03-06 1976-09-09 Mitsui Toatsu Chemicals
EP0002042B1 (de) 1977-11-16 1980-10-29 Hoechst Aktiengesellschaft Diamino-1,3,5-triazinylstilbenverbindungen, Verfahren zu deren Herstellung und ihre Verwendung als optische Aufheller
DE3216723A1 (de) * 1982-05-05 1983-11-10 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von 4,4'-bis-benz-ox(-thi,-imid)-azol-2-yl-stilbenen
AU620327B2 (en) * 1987-04-08 1992-02-20 Salutar, Inc. Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor
GB9503946D0 (en) * 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
AU6279100A (en) 1999-08-09 2001-03-05 Ciba Specialty Chemicals Holding Inc. Benzothiazole compounds and their use as optical brighteners
CZ20023562A3 (cs) * 2000-04-28 2003-03-12 Sankyo Company, Limited PPAR gama modulátory
US6720324B2 (en) * 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
CA2456868A1 (en) * 2001-08-13 2003-02-27 Henning Boettcher Inhibitors of polyq-aggregation
JP2004067659A (ja) 2002-06-12 2004-03-04 Bf Kenkyusho:Kk タウ蛋白蓄積性疾患の診断プローブとしてのベンゾイミダゾール環含有化合物
JPWO2004035522A1 (ja) 2002-08-30 2006-02-16 株式会社 ビーエフ研究所 プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤
CA2465554A1 (en) 2002-12-16 2004-06-16 Bf Research Institute, Inc. Quinoline derivatives as probes for the diagnosis of diseases in which tau protein accumulates
PT1611115E (pt) * 2003-03-14 2012-12-07 Univ Pittsburgh Compostos derivados de benzotiazole, composições e utilizações
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
US8067608B2 (en) * 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
CN101060865B (zh) 2004-07-02 2011-10-05 匹兹堡大学高等教育联邦体系 诊断淀粉样蛋白沉积相关疾病的前驱形式的方法
CA2830939C (en) 2004-07-02 2017-02-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of thioflavin radiolabelled derivatives in amyloid imaging for identifying patients prodromal to a disease associated with amyloid deposition
WO2008048205A2 (en) * 2005-06-20 2008-04-24 The Research Foundation Of State University Of New York Stor Intellectual Property Division Method for delivering hydrophobic drugs via nanocrystal formulations
CA2618360C (en) 2005-08-04 2015-06-09 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
GB0516564D0 (en) 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
WO2008014266A2 (en) * 2006-07-24 2008-01-31 University Of Maryland, Baltimore Heme oxygenase inhibitors and methods of therapeutic use
WO2008029152A2 (en) * 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
RU2364597C1 (ru) 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
EP2427463A1 (en) 2009-05-05 2012-03-14 Limited Liability Company "Innovative Pharma" Imidazo [1, 2 -a] pyridin-2 -yl-phenyl derivatives to be used in cancer treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2721845C2 (ru) * 2015-12-30 2020-05-25 Нойборон Медтех Лтд. СОЕДИНЕНИЕ ДЛЯ СПЕЦИФИЧЕСКОГО СВЯЗЫВАНИЯ С β-АМИЛОИДОМ

Also Published As

Publication number Publication date
KR20110076956A (ko) 2011-07-06
DK2338059T3 (en) 2015-06-15
MX2011002647A (es) 2011-04-07
EP2338059B1 (en) 2015-04-08
CN102224423B (zh) 2014-10-22
JP5667058B2 (ja) 2015-02-12
AU2009295701B2 (en) 2014-07-24
CN102224423A (zh) 2011-10-19
ES2540536T3 (es) 2015-07-10
CA2737028C (en) 2017-06-27
WO2010034982A1 (en) 2010-04-01
IL211369A0 (en) 2011-04-28
SI2338059T1 (sl) 2015-08-31
CA2737028A1 (en) 2010-04-01
KR101631727B1 (ko) 2016-06-17
US20110171739A1 (en) 2011-07-14
PL2338059T3 (pl) 2015-10-30
PT2338059E (pt) 2015-08-03
AU2009295701A1 (en) 2010-04-01
RU2011107931A (ru) 2012-10-27
ZA201102159B (en) 2012-10-31
EP2338059A1 (en) 2011-06-29
IL211369A (en) 2015-07-30
HK1159247A1 (en) 2012-07-27
HRP20150724T1 (hr) 2015-08-14
BRPI0919079B1 (pt) 2022-02-15
BRPI0919079A2 (pt) 2020-08-18
JP2012502966A (ja) 2012-02-02
US8895313B2 (en) 2014-11-25

Similar Documents

Publication Publication Date Title
RU2518892C2 (ru) Лиганды для агрегированных молекул тау-белка
MX2020013416A (es) Compuestos de coumarina sustituidos con amina terciaria y sus usos como etiquetas fluorescentes.
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
WO2020178162A8 (en) Exocyclic amine substituted coumarin compounds and their uses as fluorescent labels
MY164940A (en) Treatment of illitic formations using a chelating agent
MX2013006614A (es) Proceso y fluido para mejorar la permeabilidad de las formaciones de piedra arenisca al usar un agente quelante.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
GEP20125652B (en) cMET INHIBITORS
EA201100879A1 (ru) Производные пиридопиримидина в качестве ингибиторов аутотаксина
MY162022A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
UA105296C2 (ru) Определение и подсчет микроорганизмов
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
MX363538B (es) Solucion de eluyente.
CY1110943T1 (el) Νεα μεθοδος διαχωρισμου των εναντιομερων του (3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριεν-7-υλ) νιτριλιου και εφαρμογη στη συνθεση της ιβαβραδινης
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
MX2009013869A (es) Proceso para hacer 2-amino-tiazolonas sustituidas.
NO20080468L (no) Diazepinokinoliner, synteser av disse samt intermediater
PL397479A1 (pl) Nowe, fluorescencyjne barwniki heterocykliczne i sposób ich otrzymywania
MX2010007543A (es) Inhibidores de iap.
MX2010013758A (es) Procedimiento para elaborar 2-amino-tiazolonas sustituidas.
TW200738650A (en) Process for synthesis of aryloxy diaminopyrimidines
MY151042A (en) New process for obtaining the crystalline form v of agomelatine
BRPI0512558A (pt) compostos quìmicos
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina